| Orilissa (elagolix) / AbbVie |
NCT04060992: Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle |
|
|
| Unknown status | 4 | 12 | NA | Elagolix 200 MG Oral Tablet [Orilissa] | University of Southern California | Ovulation; Failure or Lack of | 10/20 | 07/21 | | |
NCT03886220: A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women |
|
|
| Completed | 4 | 82 | US | Elagolix, ABT-620, elagolix sodium, Orilissa, Placebo | AbbVie | Uterine Fibroids | 03/21 | 04/21 | | |
NCT06253702: Brain Blood Flow Responses to Stress: Sex Differences |
|
|
| Completed | 4 | 22 | US | Indomethacin, Indo, Placebo, Orilissa, Testosterone gel, Anastrozole, Estradiol | University of Wisconsin, Madison, National Heart, Lung, and Blood Institute (NHLBI) | Cerebrovascular Disorders | 05/25 | 05/25 | | |
NCT05038878: An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women |
|
|
| Terminated | 4 | 4 | US | Elagolix | Icahn School of Medicine at Mount Sinai, AbbVie | Mild Autonomous Cortisol Excess | 06/22 | 06/22 | | |
| Recruiting | 4 | 24 | US | Elagolix Oral Tablet, Orilissa, Estradiol patch, cellulose placebo, placebo patch | Penn State University | Menopause, Aging | 03/26 | 07/26 | | |
